AIHTA Appraisal Board Author Group, HTA Austria (2025): Lifileucel (AMTAGVI®) for previously treated unresectable or metastatic melanoma. Decision Support Document for the Austrian Appraisal Board 004.

AIHTA Appraisal Board Author Group, HTA Austria (2025): Obecabtagene autoleucel (AUCATZYL®) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. Decision Support Document for the Austrian Appraisal Board 005.

AIHTA Appraisal Board Author Group, HTA Austria (2025): Dorocubicel + unexpanded CD34– cells (Zemcelpro®) for the treatment of haematological malignancies in adults. Decision Support Document for the Austrian Appraisal Board 006.

AIHTA Appraisal Board Author Group, HTA Austria (2026): Tisotumab vedotin (TIVDAK®) for the treatment of adult patients with recurrent or metastatic cervical cancer. Decision Support Document for the Austrian Appraisal Board 008.

AIHTA Appraisal Board Author Group, HTA Austria (2026): Teplizumab (TEIZEILD®) for stage 2 type 1 diabetes. Decision Support Document for the Austrian Appraisal Board 007.